Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long Interspersed Nucleotide Element 1 Hypomethylation Is Associated With Poor Prognosis of Lung Adenocarcinoma  Koei Ikeda, MD, PhD, Kenji Shiraishi,

Similar presentations


Presentation on theme: "Long Interspersed Nucleotide Element 1 Hypomethylation Is Associated With Poor Prognosis of Lung Adenocarcinoma  Koei Ikeda, MD, PhD, Kenji Shiraishi,"— Presentation transcript:

1 Long Interspersed Nucleotide Element 1 Hypomethylation Is Associated With Poor Prognosis of Lung Adenocarcinoma  Koei Ikeda, MD, PhD, Kenji Shiraishi, MD, PhD, Ayami Eguchi, MT, Hidekatsu Shibata, MD, PhD, Kentaro Yoshimoto, MD, PhD, Takeshi Mori, MD, PhD, Yoshifumi Baba, MD, PhD, Hideo Baba, MD, PhD, Makoto Suzuki, MD, PhD  The Annals of Thoracic Surgery  Volume 96, Issue 5, Pages (November 2013) DOI: /j.athoracsur Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 The long interspersed nucleotide element 1 methylation levels in lung adenocarcinoma and matched normal lung specimens. The cancer tissues showed significantly lower levels of methylation than the matched normal lung (p < by the paired t test). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 (A) Kaplan-Meier curves for disease-free survival according to quartiles (Q1 to Q4) of LINE-1 methylation in lung adenocarcinoma. Q1: blue line, Q2: red line, Q3: green line, Q4: purple line. (B)(C)(D) Kaplan-Meier curves for disease-free survival; Q4 represents the “hypomethylated group” (green line) and Q1, Q2, and Q3 represent the “non-hypomethylation group” (blue line). The numbers inside the graphs represent the patients at risk in 0, 12, and 24 months after surgery. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions


Download ppt "Long Interspersed Nucleotide Element 1 Hypomethylation Is Associated With Poor Prognosis of Lung Adenocarcinoma  Koei Ikeda, MD, PhD, Kenji Shiraishi,"

Similar presentations


Ads by Google